Kaplan Thaler Wins Hush-Hush Drug Project

Just days after nabbing the $300 million Wendy’s account from Kirshenbaum Bond, Kaplan Thaler has now confirmed it’s locked a project for a drug produced by German pharma company Boehringer Ingelheim.

While the KT folks refused to comment beyond the Boehringer Ingelheim attachment, we hear the agency won the pitch for the drug Girosa, aka Flibanserin, which is reportedly used to treat Hypoactive Sexual Desire Disorder in women. Unsubstantiated rumors are afloat that the account is worth somewhere around $30 million and that Kaplan Thaler beat out pitches from CommonHealth, Grey, JWT and McCann.

More: “Kaplan Thaler Takes Home Wendy’s”

Launch a social media campaign that will build your brand and deliver results in our online Social Media Marketing Boot Camp starting June 7. Speakers include Abigail Cusick (Bravo Digital), Gregory Galant (Sawhorse Media), Alex Leo (Thomson Reuters Digital), Jim Tobin (Ignite Social Media), and many more. Read the reviews.